Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma

Research output: Contribution to journalArticle

5 Downloads (Pure)

Abstract

Eosinophils are important proinflammatory cells that make a major contribution to the inflammation seen in allergic diseases including asthma. Interleukin-5 is central to eosinophil maturation, release from the bone marrow, and subsequent accumulation, activation, and persistence in the tissues. Reslizumab (Cinquil™) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma. This review will consider the current status of the clinical development of reslizumab for asthma and in other inflammatory diseases with a marked eosinophilic component.
Original languageEnglish
Pages (from-to)7-11
Number of pages5
JournalBiologics: Targets & Therapy
Volume7
DOIs
Publication statusPublished - 9 Jan 2013

Keywords

  • IL-5
  • asthma
  • eosinophil

Fingerprint Dive into the research topics of 'Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma'. Together they form a unique fingerprint.

  • Cite this